Navigation Links
Masimo Reports First Quarter 2008 Financial Results
Date:4/29/2008

pulse rate measurements even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough noninvasive blood constituent monitoring platform that can measure many blood constituents that previously required invasive procedures. Rainbow SET continuously and noninvasively measures total hemoglobin (SpHb(TM)) and oxygen content (SpOC(TM)) (both pending regulatory clearances), carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and PVI(TM), in addition to oxyhemoglobin (SpO2), pulse rate (PR), and perfusion index (PI), allowing early detection and treatment of potentially life-threatening conditions. Founded in 1989, Masimo has the mission of "Improving Patient Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications." Additional information about Masimo and its products may be found at http://www.masimo.com.

Forward-Looking Statements

This press release includes forward-looking statements. All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements including, in particular, the statements about: our financial condition, results of operations, prospects and business generally; the market acceptance of our technologies and products; the value of measuring new parameters; expectations regarding our ability to design and deliver innovative new noninvasive technologies; and expectations for total revenues, product revenues, GAAP earnings per share, non-GAAP pro forma earnings per share and stock based compensation expenses for the full fiscal year 2008. These forward-looking statements are based on management's current expectations and beliefs and are subject to uncertainties and factors, all
'/>"/>

SOURCE Masimo Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Atom Medical Adopts Masimo Rainbow SET Technology
2. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
3. Masimo to Present at Citi Investment Research 5th Annual Small & Mid-Cap Conference
4. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
5. Masimo Announces Continuous Noninvasive Total Hemoglobin
6. Masimo Awarded Multi-Year Pulse Oximetry Agreement with HealthTrust Purchasing Group
7. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. Masimo Corporation Given Approval to Market the Masimo Rad-57 Pulse CO-Oximeter in Japan
9. Masimo to Report Third Quarter 2007 Financial Results on October 30, 2007
10. Masimo Launches Patient SafetyNet and Showcases the Rainbow SET Upgradable Noninvasive Monitoring Platform at 2007 ASA Annual Meeting
11. Masimo Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... the University of Leicester has furthered our understanding ... to create new materials using nanosized ,building blocks,. ... the prestigious academic journal Physical Review Letters ... in rich detail the structure and internal atomic ... molecule and a single helium atom. , The ...
(Date:7/25/2014)... Lawrence Livermore scientists Charles Westbrook and William ... " The World's Most Influential Scientific Minds ." , ... who were identified by analyzing citation data over the ... highest-impact work (2002-2012 and 2012-2013). The two were selected ... . , "This recognition is a great honor for ...
(Date:7/24/2014)... NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. ... the long-term, randomized, active control Phase 3 study of ... phosphate binder, for the treatment of hyperphosphatemia in patients ... study (PhosphatE binding and iRon delivery with FErric CiTrate ... Journal of the American Society of Nephrology ( ...
(Date:7/24/2014)... 2014  ECC West Africa, LLC (ECC) signed a ... University College Hospital (UCH) Ibadan Board of Management for ... design, construct, and operate and maintain a new, state-of-the-art ... Under the first of the 4-phase project, ECC will ... applications. UCH Ibadan intends to finance and develop the ...
Breaking Biology Technology:Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 2Breakthrough laser experiment reveals liquid-like motion of atoms in an ultra-cold cluster 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... to also Raise $7.5 Million in Non-Dilutive Financing from, ... 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) ... a definitive agreement, subject to shareholder and regulatory approvals, whereby ... and merger to continue as a publicly-traded entity to be ...
... , SHANGHAI, Aug. 17 /PRNewswire-Asia-FirstCall/ -- ... leading Chinese firm,specializing in the manufacture, research, development, marketing and,distribution ... quarter of its 2010 fiscal year, ended June 30, 2009. ... -- Net sales increased 35.5% year-over-year to $15.4 ...
... a "spaser," is the first of its kind to ... possible future technologies based on "nanophotonic" circuitry, said Vladimir ... and Computer Engineering at Purdue University. Such circuits ... be made small enough to integrate them into electronic ...
Cached Biology Technology:Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 2Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 3Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 4Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 5Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 6Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 7Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 8Vasogen and IntelliPharmaCeutics to Combine to Create Publicly-traded Specialty Pharmaceutical Company 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports First Quarter Fiscal 2010 Financial Results 11New nanolaser key to future optical computers and technologies 2New nanolaser key to future optical computers and technologies 3
(Date:7/24/2014)... smog-free Los Angeles, where electric cars ply silent freeways, ... heat from beneath the earth, from howling winds and ... study finds that it is technically and economically feasible ... by clean, renewable energy. Published in Energy , ... and reliable energy supply in California that could create ...
(Date:7/24/2014)... at Albert Einstein College of Medicine of ... J. Fox Foundation for Parkinson,s Research to translate a ... This drug discovery project will test chemical compounds on ... a drug that acts on an underlying cause of ... help many people manage their symptoms, we are eager ...
(Date:7/24/2014)... in the United States, wildland managers often utilize the ... trees (ladder fuels). These cuttings and other post-logging ... danger in order to dispose of the material. To ... often cover all or part of the debris pile ... plastic, in order to keep water out. A recent ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3Study gives new perspective on agricultural plastic, debris burning, and air quality 2
... too much growth in patients has now also been ... can lead to very different conditions, according to research ... IMAGe* syndrome is a rare developmental disorder which ... body and organ size. Without treatment, the disorder can ...
... climate change because they don,t understand the science behind ... more proficient in technical reasoning, would public consensus match ... the journal Nature Climate Change suggests that ... members of the public become more science literate and ...
... see how a common house sparrow and a Tyrannosaurus Rex might ... weighs less than an ounce, and the other is a dinosaur ... scales at more than eight tons. For all their ... than many believed. A new study, led by Harvard scientists, has ...
Cached Biology News:Variations of a single gene can lead to too much or too little growth, study shows 2Yale study concludes public apathy over climate change unrelated to science literacy 2Timing is everything 2Timing is everything 3Timing is everything 4